Effectiveness of Phenolic Antioxidants in Experimental Model of Benign Prostatic Hyperplasia
- Авторы: Borovskaya T.1, Kamalova S.1, Grigor’eva V.1, Poluektova M.1, Vychuzhanina A.1, Kuchin A.2, Chukicheva I.2, Buravlev E.2, Fomina T.1, Plotnikov M.1, Goldberg V.3, Dygai A.1
-
Учреждения:
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
- Institute of Chemistry, Komi Scientific Center, Ural Division of Russian Academy of Sciences
- Research Institute of Oncology, Tomsk National Research Medical Center
- Выпуск: Том 167, № 5 (2019)
- Страницы: 606-609
- Раздел: General Pathology and Pathological Physiology
- URL: https://journals.rcsi.science/0007-4888/article/view/241957
- DOI: https://doi.org/10.1007/s10517-019-04580-3
- ID: 241957
Цитировать
Аннотация
Experimental model of sulpiride-provoked benign prostatic hyperplasia was employed to comparatively assess the effect of phenolic antioxidants (dihydroquercetin, p-thyrozol, dibornol, and prostagenin) on prostate morphology. All examined agents decreased the degree of hyperplasia in acinar epithelium; the greatest efficacy was demonstrated by prostagenin. Moreover, dihydroquercetin and p-thyrozol increased the cross-section area of acinar lumina and prostate volume, which is inadmissible in this pathology. These results suggest that the use of phenolic antioxidants in the therapy of benign prostatic hyperplasia should be strictly controlled.
Об авторах
T. Borovskaya
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Автор, ответственный за переписку.
Email: repropharm@yandex.ru
Россия, Tomsk
S. Kamalova
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: repropharm@yandex.ru
Россия, Tomsk
V. Grigor’eva
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: repropharm@yandex.ru
Россия, Tomsk
M. Poluektova
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: repropharm@yandex.ru
Россия, Tomsk
A. Vychuzhanina
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: repropharm@yandex.ru
Россия, Tomsk
A. Kuchin
Institute of Chemistry, Komi Scientific Center, Ural Division of Russian Academy of Sciences
Email: repropharm@yandex.ru
Россия, Syktyvkar
I. Chukicheva
Institute of Chemistry, Komi Scientific Center, Ural Division of Russian Academy of Sciences
Email: repropharm@yandex.ru
Россия, Syktyvkar
E. Buravlev
Institute of Chemistry, Komi Scientific Center, Ural Division of Russian Academy of Sciences
Email: repropharm@yandex.ru
Россия, Syktyvkar
T. Fomina
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: repropharm@yandex.ru
Россия, Tomsk
M. Plotnikov
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: repropharm@yandex.ru
Россия, Tomsk
V. Goldberg
Research Institute of Oncology, Tomsk National Research Medical Center
Email: repropharm@yandex.ru
Россия, Tomsk
A. Dygai
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: repropharm@yandex.ru
Россия, Tomsk